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Introduction: Heparin is safe and prevents venous thromboembolism in critical illness. We aimed to determine the
guideline concordance for thromboprophylaxis in critically ill patients and its predictors, and to analyze factors
associated with the use of low molecular weight heparin (LMWH), as it may be associated with a lower risk of
pulmonary embolism and heparin-induced thrombocytopenia without increasing the bleeding risk.
Methods: We performed a retrospective audit in 28 North American intensive care units (ICUs), including all
consecutive medical-surgical patients admitted in November 2011. We documented ICU thromboprophylaxis
and reasons for omission. Guideline concordance was determined by adding days in which patients without
contraindications received thromboprophylaxis to days in which patients with contraindications did not receive it,
divided by the total number of patient-days. We used multilevel logistic regression including time-varying, center
and patient-level covariates to determine the predictors of guideline concordance and use of LMWH.
Results: We enrolled 1,935 patients (62.3 ± 16.7 years, Acute Physiology and Chronic Health Evaluation [APACHE]
II score 19.1 ± 8.3). Patients received thromboprophylaxis with unfractionated heparin (UFH) (54.0%) or LMWH
(27.6%). Guideline concordance occurred for 95.5% patient-days and was more likely in patients who were sicker
(odds ratio (OR) 1.49, 95% confidence interval (CI) 1.17, 1.75 per 10-point increase in APACHE II), heavier (OR 1.32,
95% CI 1.05, 1.65 per 10-m/kg2 increase in body mass index), had cancer (OR 3.22, 95% CI 1.81, 5.72), previous
venous thromboembolism (OR 3.94, 95% CI 1.46,10.66), and received mechanical ventilation (OR 1.83, 95% CI
1.32,2.52). Reasons for not receiving thromboprophylaxis were high risk of bleeding (44.5%), current bleeding
(16.3%), no reason (12.9%), recent or upcoming invasive procedure (10.2%), nighttime admission or discharge
(9.7%), and life-support limitation (6.9%). LMWH was less often administered to sicker patients (OR 0.65, 95% CI
0.48, 0.89 per 10-point increase in APACHE II), surgical patients (OR 0.41, 95% CI 0.24, 0.72), those receiving
vasoactive drugs (OR 0.47, 95% CI 0.35, 0.64) or renal replacement therapy (OR 0.10, 95% CI 0.05, 0.23).
Conclusions: Guideline concordance for thromboprophylaxis was high, but LMWH was less commonly used,
especially in patients who were sicker, had surgery, or received vasopressors or renal replacement therapy,
representing a potential quality improvement target.* Correspondence: debcook@mcmaster.ca
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Thromboprophylaxis is a key component of care for crit-
ically ill patients because of their high risk of venous
thromboembolism [1] and because heparin is an effect-
ive and safe prevention strategy. The Stanford University
Evidence Based Practice Center rates thromboprophy-
laxis as the foremost patient safety initiative for hospital-
ized patients [2]. Moreover, the Joint Commission now
specifies thromboprophylaxis as a key quality measure
for hospitalized patients [3] and thromboprophylaxis is
also a hospital accreditation metric in Canada [4].
Analysis of a large registry of 175,665 critically ill adult
patients in 134 ICUs in Australia and New Zealand from
2006 to 2010 showed a significant association between
omission of early thromboprophylaxis and hospital mor-
tality after adjusting for covariates, including multiple
trauma, sepsis, cardiac arrest, and preexisting metastatic
cancer [5]. From a patient and healthcare system per-
spective, ascertaining current practice and ensuring that
it is commensurate with current best evidence is crucial.
We therefore conducted a multicenter audit of thrombo-
prophylaxis in medical–surgical critically ill patients to
identify the types and rates of thromboprophylaxis and
to analyze factors associated with appropriate use. We
hypothesized that approximately 80% of patients would
receive some anticoagulant, reflecting approximately
70% of eligible ICU-days, and that low molecular weight
heparin (LMWH) would be used less than unfractio-
nated heparin (UFH) [6].
Materials and methods
Design
We conducted a multicenter retrospective 1-month prac-
tice audit of all consecutive patients admitted to the ICU
between 1 November and 30 November 2011 in 26 cen-
ters across Canada and two centers in the United States to
record thromboprophylaxis practices. We excluded pa-
tients admitted for less than 12 hours and patients admit-
ted directly from the operating or recovery room after a
cardiac surgery or neurosurgical procedure.
Pilot reliability study
Case report forms and an implementation manual were
developed and pretested by two research coordinators,
adapted from prior studies [7,8]. We conducted a struc-
tured, independent, duplicate chart abstraction exercise
to identify points of data disagreement, to clarify meth-
odology, and to enhance the efficiency and validity of
the audit process. Two research coordinators from eight
participating centers reviewed the case report forms and
implementation manual, and then each independently
audited five charts, abstracting 27 baseline demographic
variables and 30 daily data variables for each patient’s
length of ICU stay, which ranged from 2 to 60 days.Only 2% of variables were discordant overall. This cali-
bration exercise mitigated discordance within and across
centers, and improved the operational efficiency of the
audit [9].Audit
Data were abstracted until death or ICU discharge, cen-
sored at 60 days. Trained research coordinators collected
demographics and baseline characteristics (age, sex, Acute
Physiology and Chronic Health Evaluation (APACHE)
II score [10], medical vs. surgical status, ICU admitting
diagnosis), and relevant clinical outcomes (deep vein
thrombosis, pulmonary embolism, major bleeding [11],
heparin-induced thrombocytopenia, mortality). Venous
thromboembolism events were diagnosed by the treat-
ing physicians based on clinical judgment and objective
testing.
Pharmacologic prophylaxis (UFH, LMWH, warfarin,
danaparoid, other agents), mechanical prophylaxis (antiem-
bolic stockings, pneumatic compression devices), thera-
peutic anticoagulation, antiplatelet treatments, and use of
inferior vena cava filters were captured daily, as well as
factors potentially modulating prescribing such as la-
boratory values (for example, platelet count), outcomes
(for example, bleeding), confirmatory tests (for all venous
thromboembolism events), and process of care variables
(for example, mobility). We also recorded characteristics
of participating centers, including the number of ICU
beds, the presence of a dedicated thrombosis service,
trauma service or ICU quality improvement team, and
whether thromboprophylaxis was administered using pre-
printed orders or computerized physician order entry.Adjudication
Venous thromboembolism events and bleeding events
were adjudicated by one investigator unaware of the
use of thromboprophylaxis using established and vali-
dated classification systems. For venous thromboembol-
ism events, recent trial definitions were used [12].
Bleeding was classified as major if it was life threatening
due to hypovolemic shock (for example, ruptured abdom-
inal aortic aneurysm) or at a critical site (for example,
intracranial), if the bleeding was overtly clinically import-
ant and was associated with one of several criteria within
24 hours of the bleed (decrease in hemoglobin >20 g/l,
transfusion ≥2 packed red blood cells, decrease in systolic
blood pressure >20 mmHg, or increase in heart rate >20
bpm in the absence of other causes), or if the bleeding re-
quired an invasive intervention (for example, reoperation)
[11,12]. Heparin-induced thrombocytopenia was diag-
nosed by serotonin release assay [13]. Thrombosis was
attributed to heparin-induced thrombocytopenia if it oc-
curred within 1 week of the positive serologic test.
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We reported continuous data as the mean and standard
deviation or the median and interquartile range when
data were skewed. We reported absolute numbers of pa-
tients or days, and proportions. We used t tests and
Wilcoxon rank-sum tests to compare continuous data
and Fisher’s exact test to compare proportions.
We analyzed thromboprophylaxis overall and by cen-
ter. Our primary outcome was guideline concordance
with the 2008 American College of Chest Physicians
Antithrombotic Therapy and Prevention of Thrombosis
Guidelines’ 1A recommendation for daily heparin throm-
boprophylaxis (either UFH or LWMH) for all critically ill
patients unless contraindications exist [14]. We calculated
a guideline concordance rate for any type of heparin
prophylaxis (UFH or LWMH) or therapeutic heparin, in
those patients receiving it, by center and overall. Specific-
ally, guideline concordance was defined as ICU days in
which eligible patients for any type of pharmacologic
thromboprophylaxis (any ICU patient without contraindi-
cations) were receiving it as recommended, plus noneligi-
ble patients who were not receiving it as recommended,
divided by the total number of ICU patient-days. By eli-
gible patients, we refer to those being in the ICU with
no contraindications to pharmacologic prophylaxis (for
example, active bleeding, high risk of bleeding, sus-
pected or proven heparin-induced thrombocytopenia,
or imminent or recent invasive procedure within 24
hours). Other reasons or no clear reasons were not con-
sidered contraindications.
To analyze the factors associated with guideline con-
cordance, we used multilevel logistic regression, analyzing
repeated measurements of concordance within patients
and within centers. Possible determinants included two
factors at the level of center (dedicated thrombosis service,
use of preprinted orders), five factors at the level of pa-
tients (medical versus surgical admission, APACHE II
score, cancer, history of venous thromboembolism events,
or body mass index), and three time-varying factors at
the level of patient-days (invasive mechanical ventila-
tion, inotropes or vasopressors, and renal replacement
therapy). Patient factors were therefore measured at ei-
ther baseline (for example, cancer) or on a daily basis
(for example, renal replacement therapy). We calculated
odds ratios (ORs) and 95% confidence intervals (CIs). We
considered factors significant at the P < 0.05 level.
In a second regression analysis, we examined factors
associated with LMWH thromboprophylaxis rather than
UFH thromboprophylaxis, including only those patient-
days on which the patient received doses of either agent.
This was based on a recent systematic review of random-
ized trials of LMWH versus UFH in medical–surgical pa-
tients performed by our group [15]. We considered the
same covariates as in the first regression.Research ethics
This retrospective audit was reviewed and approved by
each participating center’s Research Ethics Board (see
Acknowledgements), waiving the need for informed
consent.
Results
We enrolled patients from 26 Canadian centers and two
US centers. The centers contributed a median (inter-
quartile range) of 55.5 (42.5, 74.0) patients to the audit.
Participating centers had a mean (standard deviation) of
22.6 (9.8) ICU beds. Among the 28 centers, a dedicated
thrombosis service existed in nine centers (32.1%), a
dedicated trauma service in 17 centers (60.7%), and a
dedicated ICU quality improvement team in 19 centers
(67.9%). Thromboprophylaxis prescribing was facilitated
by preprinted orders in 21 centers (75.0%), and by com-
puterized physician order entry in six centers (21.4%).
We included 1,935 patients (mean age 62.3 ± 16.7)
with a mean APACHE II score of 19.1 ± 8.3. Baseline
characteristics are shown in Table 1 and patient out-
comes in Table 2. Venous thromboembolic events were
uncommon: leg thrombi (42 patients, 2.2%), nonleg
thrombi (52 patients, 2.7%), and pulmonary embolism
(36 patients, 1.9%). Heparin-induced thrombocytopenia
occurred in two patients (0.001%), associated with ven-
ous thromboembolic events in both. Major bleeding oc-
curred in 187 patients (9.7%). Among these patients, 74
were receiving either LMWH or UFH for thrombopro-
phylaxis on their first day of bleeding. Mortality was
12.5% (242 patients) in the ICU and 19.4% (375 patients)
in hospital.
Overall, 1,619 patients (83.7%) received some form
of anticoagulant during their ICU stay. Pharmacologic
thromboprophylaxis was with UFH in 1,044 patients
(54.0%) or with LMWH in 535 patients (27.6%), whereas
390 patients (20.2%) were therapeutically anticoagulated
at some time with UFH, warfarin, LMWH, or danapar-
oid for venous thromboembolism or other indication
such as atrial fibrillation and acute coronary syndrome
(Table 3). When considering patient-days as the unit of
analysis, prophylaxis patterns were similar. Pharmaco-
logic prophylaxis was administered for 65.4% of patient-
days. There were 1,957 of 12,756 patient-days (15.3%)
during which no thromboprophylaxis (neither pharma-
cologic nor mechanical) was administered (Figure 1).
We documented guideline concordance for 12,186/
12,756 (95.5%) patient-days. The range of guideline con-
cordance in participating centers ranged from 81.3 to
100.0%. The highest level of patient activity during these
570 patient-days of nonconcordance included bed rest
(363 patient-days, 64.0%), transferring to a chair (100
patient-days, 17.5%), and walking (105 patient-days, 18.4%),
with data missing for 2 patient-days. The respiratory status
Table 1 Baseline patient characteristics
Characteristic All patients (n = 1,935)
Age (years) 62.3 (16.7)












Other medical 71 (3.7)
Other surgical 80 (4.1)
Location prior to ICU
Operating room/recovery room 485 (25.1)
Emergency room 669 (34.6)
Ward 480 (24.8)
Other hospital ICU 83 (4.3)
Other hospital ward 218 (11.3)
Medical admission 1453 (75.1)
Mechanical ventilation
Invasive 997 (51.5)




Data presented as mean (standard deviation) or number (percentage).
Characteristics of the 1,935 patients included in this audit on the first day of
ICU admission, from 28 participating ICUs. APACHE, Acute Physiology and
Chronic Health Evaluation.
Table 2 Patient outcomes
Outcome All patients (n = 1,935)
Major outcomes
ICU mortality 242 (12.5)
Hospital mortality 375 (19.4)
Re-admitted to ICU 55 (2.8)
ICU length of stay (days) 4 (2 to 7)
Hospital length of stay (days) 12 (6 to 24)
Adjudicated outcomes
Leg thrombus 42 (2.2)
Nonleg thrombusa 52 (2.7)
Pulmonary embolism 36 (1.9)
Any venous thromboembolism 117 (6.0)
Heparin-induced thrombocytopenia 3 (0.2)
Major bleeding 187 (9.7)
Any bleeding 457 (23.6)
Data presented as number (percentage) or median (interquartile range).
Venous thromboembolic outcomes, length of stay and mortality status of the
1,935 patients included in this audit, from 28 participating ICUs. Only the first
ICU admissions during the audit month were considered. Outcomes are not
mutually exclusive. aThromboses occurring in sites other than the lower
extremities, including the head and neck, trunk, and upper extremities.






Subcutaneous LMWH 535 (27.6) 2,687 (21.1)
Subcutaneous UFHa 1,044 (54.0) 5,504 (43.1)
Therapeutic anticoagulants
Any therapeutic anticoagulant 390 (20.2) 1,693 (13.3)
Intravenous UFH 284 (14.7) 1,210 (9.5)
LMWH 35 (1.8) 119 (0.9)
Coumadin 94 (4.9) 324 (2.5)
Danaparoid 5 (0.3) 7 (0.05)
Otherb 52 (2.7) 168 (1.3)
Any of the above 1,619 (83.7) 9,589 (75.2)
Anticoagulation management for the 1,935 patients included in this audit, and
ICU patient-days. Some patients received more than one type of anticoagulation
during their ICU stay. LMWH, low molecular weight heparin; UFH, unfractionated
heparin. aRefers to doses of UFH that were not ordered to target an activated par-
tial thromboplastin time. bThrombolytic agents (streptokinase, recombinant tissue
plasminogen activator), argatroban, fondaparinux, eptifibatide, dabigatran,
rivaroxaban.
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breathing (331 patient-days, 58.1%), non-invasive venti-
lation (215 patient-days, 37.7%), and invasive mechan-
ical ventilation (24 patient-days, 4.2%). We did not
identify any patients who received heparin when it was
contraindicated.
Factors associated with guideline concordance with
thromboprophylaxis are reported in Table 4. Guideline
concordance was more likely in patients who were sicker
(OR = 1.49, 95% CI = 1.17, 1.75 for each 10-point in-
crease in APACHE II score), in patients who were heav-
ier (OR = 1.32, 95% CI = 1.05, 1.65 for each 10-point
increase in body mass index), in patients with cancer
(OR = 3.22, 95% CI = 1.81, 5.72), in patients with a his-
tory of venous thromboembolism (OR = 3.94, 95%CI = 1.46, 10.66), and among those receiving mechan-
ical ventilation (OR = 1.83, 95% CI = 1.32, 2.52).
For 3,167 patient-days (24.8%) where no form of anti-
coagulant was administered, the reasons given were high
risk of bleeding (44.5%), bleeding (16.3%), no reason evi-
dent (12.9%), invasive procedure (10.2%), nighttime admis-
sion to or discharge from the ICU (9.7%), life-support





Figure 1 Thromboprophylaxis strategy in medical–surgical
patients. Proportions of patient-days for each thromboprophylaxis
strategy used (pharmacological, mechanical, combined, none).
Table 5 Reason for not using anticoagulant
Reason 3,167 patient-days with no
anticoagulant
High risk of bleeding 1,410 (44.5)
Bleeding 517 (16.3)
Invasive procedure/surgery 324 (10.2)
Nighttime admission or discharge 306 (9.7)
Limiting life support 218 (6.9)





No reason evident 408 (12.9)
Reasons for no anticoagulation for 3,167 patient-days among 1,116 patients.
aExamples include severe anemia, mildly abnormal laboratory values, prescrib-
ing omission, pharmacy error, expected short-term ICU admission, ambulation,
and patient declined.
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thrombocytopenia (1.4%) (Table 5).
Factors associated with prescription of LMWH instead
of UFH per patient-day are reported in Table 6. LMWH
was less likely used than UFH in sicker patients (OR =
0.65, 95% CI = 0.48, 0.89 for each 10-point increase in
APACHE II score), in surgical patients versus medical
patients (OR = 0.41, 95% CI = 0.24, 0.72), in those receiv-
ing inotropes or vasopressors (OR = 0.47, 95% CI = 0.35,
0.64), and in patients receiving renal replacement ther-
apy (OR = 0.10, 95% CI = 0.05, 0.23).Table 4 Factors associated with guideline concordance:
multilevel logistic regression




Surgical admission 1.09 (0.68, 1.75) 0.718
APACHE II score (10-point increase) 1.49 (1.17, 1.89) 0.001
Cancera 3.22 (1.81, 5.72) <0.001
History of venous thromboembolism 3.94 (1.46, 10.66) 0.007
Body mass index (10-point increase) 1.32 (1.05, 1.65) 0.018
Daily factorsb
Any dialysis 0.79 (0.45, 1.40) 0.422
Invasive mechanical ventilation 1.83 (1.32, 2.52) <0.001
Vasopressors or inotropes 1.26 (0.90, 1.78) 0.184
Site factors
Dedicated thrombosis consulting service 1.91 (0.95, 3.86) 0.069
Preprinted orders including
thromboprophylaxis
1.00 (0.51, 1.98) 0.989
Results of the multilevel logistic regression model examining determinants of
guideline concordance (use of any pharmacological thromboprophylaxis
unless contraindications exist). The three levels are center, patient, and ICU-
day. There were 10,540 patient-days (10,154 with concordance, 386 without),
n = 1,533 patients. Body mass index values were missing for 402 of the 1,935
patients enrolled in the study. These patients were therefore excluded from
the regression analysis. APACHE, Acute Physiology and Chronic Health Evaluation;
CI, confidence interval. aCancer refers to lymphoma, metastatic cancer, leukemia,
multiple myeloma, active solid malignancy, or history of solid malignancy. bDaily
factors reflect exposure in the preceding 3 days.Mechanical prophylaxis was ordered less often than
pharmacologic prophylaxis (5.5% patient-days for anti-
embolic stockings and 16.5% patient-days for pneumatic
compression devices). These two devices were most
often ordered when no anticoagulant was administered
(Figure 2). More specifically, anti-embolic stockings were
administered for 8.3% patient-days, and pneumatic com-
pression devices on 34.8% patient-days. Overall, thereTable 6 Factors associated with LMWH rather than UFH
thromboprophylaxis: multilevel logistic regression




Surgical admission 0.41 (0.24, 0.72) 0.002
APACHE II score (10-point increase) 0.65 (0.48, 0.89) 0.007
Cancera 1.12 (0.64, 1.94) 0.692
History of venous thromboembolism 1.18 (0.50, 2.76) 0.704
Body mass index (10-point increase) 1.12 (0.88, 1.44) 0.362
Daily factorsb
Any dialysis 0.10 (0.05, 0.23) <0.001
Invasive mechanical ventilation 0.77 (0.56, 1.06) 0.105
Vasopressors or inotropes 0.47 (0.35, 0.64) <0.001
Site factors
Dedicated thrombosis consulting service 4.20 (0.62, 28.60) 0.135
Preprinted orders including
thromboprophylaxis
1.79 (0.24, 13.44) 0.556
Results of the multilevel logistic regression model examining determinants of
LMWH rather than UFH thromboprophylaxis. The three levels are center,
patient, and ICU-day. There were 6,856 patient-days (2,182 with LMWH
prophylaxis), n = 1,181 patients. Body mass index values were missing for 402
of the 1,583 patients who received thromboprophylaxis. These patients were
therefore excluded from the regression analysis. APACHE, Acute Physiology
and Chronic Health Evaluation; CI, confidence interval; LMWH, low molecular
weight heparin; UFH, unfractionated heparin. aCancer refers to lymphoma,
metastatic cancer, leukemia, multiple myeloma, active malignancy, or history















Figure 2 Mechanical prophylaxis according to concomitant
pharmacologic thromboprophylaxis. Proportions of patient-days
for each type of mechanical thromboprophylaxis used (anti-embolic
stockings, pneumatic compression, either type) depending on the
use of concomitant pharmacological thromboprophylaxis.
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anical prophylaxis (anti-embolic stockings and pneumatic
compression devices) and pharmacological prophylaxis
were applied. Inferior vena cava filters were inserted in 31
patients (1.6%), for a total of 157 patient-days. Two-thirds
of inferior vena cava filters were inserted prophylactically
(21/31 filters, 67.7%), and two patients developed a leg
deep venous thrombosis after the filter insertion during
their ICU stay.
Discussion
In this 1-month multicenter audit, we observed a guide-
line concordance for pharmacological thromboprophy-
laxis for 95.5% of ICU-days in medical–surgical critically
ill patients. Guideline concordance for pharmacological
thromboprophylaxis was more likely in sicker and heav-
ier patients, and in patients with cancer, with a history
of venous thromboembolism, and those receiving mech-
anical ventilation. LMWH was less commonly used than
UFH, especially in patients who were sicker, who had
surgery, or who received vasoactive drugs or renal re-
placement therapy.
The guideline concordance documented in this audit
was somewhat higher than previous audits [7,16]. This
increased concordance may reflect the growing number
of randomized trials supporting the use of heparin in
various populations, including in the ICU. Time has
allowed for the passive diffusion of evidence into prac-
tice, and generalized application of heparin thrombopro-
phylaxis. The encoding of thromboprophylaxis into
hospital accreditation may also play a role. Our findings
may reflect the low cost of heparin relative to other pre-
ventive or therapeutic interventions used in the ICU.
High guideline concordance of pharmacologic thrombo-
prophylaxis as a relatively simple intervention contrastswith some other multifaceted quality improvement initia-
tives such as ventilator-associated pneumonia prevention
[17] for which there are several components (for example,
body position, mechanical interventions, pharmacologic
approaches).
Use of pharmacologic thromboprophylaxis was signifi-
cantly more likely in patients with high illness severity, a
diagnosis of cancer, a history of venous thromboembol-
ism event, and a high body mass index. Clinician aware-
ness of risk factors may have driven the higher penetrance
of pharmacologic thromboprophylaxis use for patients
with these characteristics. Prior critical care research has
shown that the risk of a venous thromboembolism event
is greater in patients with a high APACHE II score [18],
cancer [19], personal or family history of venous thrombo-
embolism [20,21], and greater weight [22-24]. Inadequate
dosing in obese patients leading to lower anti-Xa levels
[25] may explain this association [26,27]. Of the three
advanced life supports examined, only mechanical ven-
tilation was significantly associated with guideline con-
cordance, possibly reflecting perceived higher risk of a
venous thromboembolism event in mechanically venti-
lated patients [28,29]. In terms of center effects, neither
the presence of a dedicated thrombosis consulting ser-
vice nor the use of preprinted orders was associated
with guideline concordance, adjusting for other patient-
specific factors. Although drug-prescribing modifica-
tion is amenable to preprinted orders, the impact has
not been well studied in the ICU.
As hypothesized, LMWH was administered less often
than UFH, which is consistent with a national Austrian
audit of 325 critically ill patients documenting lower use
of LMWH [30]. In early 2013, the Surviving Sepsis Cam-
paign issued a 1B recommendation to use LMWH daily
thromboprophylaxis instead of UFH twice-daily throm-
boprophylaxis in the absence of contraindications [31].
This recommendation was partly based on the multi-
national Prophylaxis for Thromboembolism in Critical
Care Trial (PROTECT) in 3,764 critically ill patients
showing that dalteparin significantly reduced the risk of
pulmonary embolism in critically ill patients compared
with UFH, with no difference in major bleeding and a
trend toward lower rates of deep vein thrombosis, overall
venous thromboembolism events, and heparin-induced
thrombocytopenia [12]. Subsequently, a recent meta-
analysis of five randomized trials enrolling more than
5,000 medical–surgical critically ill patients showed that
LMWH reduced rates of overall and symptomatic pul-
monary embolism compared with UFH, but not overall
and symptomatic deep venous thrombosis or mortality,
while major bleeding was not different [15]. The gap in
care regarding the use of LMWH is moderately large,
and may represent a quality improvement target. A
prospective economic evaluation conducted alongside
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prophylaxis was the least costly strategy until the cost of
dalteparin rose from a base case cost of $8.13 to $183 per
dose (R Fowler et al., Cost-effectiveness of dalteparin ver-
sus unfractionated heparin for the prevention of venous
thromboembolism in critically ill patients: a prospective
comparative economic evaluation of the Prophylaxis for
Thromboembolism in Critical Care Trial (PROTECT),
submitted). There was no threshold in which lowering the
acquisition cost of UFH favored this prophylaxis strategy.
In our study, patients receiving inotropes or vasopres-
sors were 50% less likely to receive LMWH than UFH.
Such patients are at higher risk of venous thromboembol-
ism [20], possibly due to the concomitant proinflamma-
tory and procoagulant state, or decreased subcutaneous
heparin bioavailability as suggested by lower anti-Xa levels
[32,33] related to peripheral blood shunting or edema
[34]. LMWH may be less likely prescribed to patients re-
ceiving inotropes or vasopressors due to fear of bleeding,
as these patients have lower platelet counts, higher Inter-
national Normalized Ratio values, and higher partial
thromboplastin time values than those not receiving ino-
tropes or vasopressors. Surgical patients were also less
likely to receive LMWH than UFH compared with med-
ical patients, which may reflect concern about increased
risk of postoperative bleeding. This situation is paradoxical
in that the relative benefit of LMWH over UFH is stronger
in surgical populations [35] than in medical populations
[1]. Patients receiving renal replacement therapy were also
significantly less likely to receive LMWH than UFH. This
could reflect concern about LMWH bioaccumulation in
renal insufficiency. However, dalteparin 5,000 U subcuta-
neously does not bioaccumulate, as demonstrated by un-
detectable mean anti-Xa levels in a multicenter study of
ICU patients with a range of renal dysfunction including
anuric renal failure [36]. Similarly, when administered at
prophylactic doses to patients with a range of renal
function, prophylactic tinzaparin did not bioaccumulate
whereas enoxaparin did [37].
Mechanical thromboprophylaxis with either anti-embolic
stockings or pneumatic compression devices was infre-
quent. Mechanical thromboprophylaxis was primarily
used in patients who were currently bleeding or at risk
of bleeding, which is congruent with the American
College of Chest Physicians 2012 recommendation to
use mechanical thromboprophylaxis for patients with
contraindications to heparin [1], and the Grade 2C
Surviving Sepsis Campaign recommendation [31]. Our
observation that 6% and 17% of patient-days involved
anti-embolic stockings and pneumatic compression de-
vices, respectively, highlights the frequency of contraindi-
cations to pharmacological prophylaxis in medical–surgical
patients. This observation also underscores the need
for higher quality research on the effectiveness ofmechanical prophylaxis, given the sparse data support-
ing their efficacy in this population [38]. Despite rec-
ommendations against the use of inferior vena cava
filters for venous thromboembolism events and prophy-
laxis [14,36,39] and clear evidence that they cause
thrombosis, the filters continue to be widely used for
prevention. Although we did not examine removal rates
in this audit, it is also concerning in real-world practice
that less than 20% of retrievable filters are actually re-
moved [40].
This study has several limitations. We could not in-
corporate physician factors as determinants of docu-
mented prophylaxis because physicians are numerous in
the ICU on any given day (for example, attending, fel-
low, resident) and prescribers change often throughout a
patient’s ICU stay, precluding the attribution of drug
prescribing to one physician on any given day or for any
given patient. Given the retrospective design, we could
not concurrently survey clinicians to determine the ra-
tionale for their prescribing choices. We did not collect
data after ICU discharge. In one observational study,
survivors with resolving critical illness were less likely to
receive thromboprophylaxis on the ward compared with
within the ICU [29]. Finally, our collaboration with North
American centers could to some extent explain why
prophylactic UFH was preferentially used over LMWH,
because LMWH was adopted sooner in Europe [41].
This study has several strengths. By building on our re-
cent research to document [7,8], understand [42], imple-
ment [43], and test [12,37] thromboprophylaxis in the ICU,
we examined whether and how clinicians use heparin
thromboprophylaxis in this audit. There were several fea-
tures of this study that contributed to its success – related
to the project itself (relevant topic, simple design, manage-
able amount of data), the operations (a supportive methods
center, user-friendly tools, formal training, provision of re-
sults to participating centers, funding), and the centers
(commitment, skilled personnel, membership in a network
in which the audit is embedded) [44]. Furthermore, we
provided each participating hospital with patient-centered,
site-specific data formulated as a quality improvement
metric of guideline concordance designed for heparin
thromboprophylaxis. The metric reflected individualized
pharmacotherapeutic care and incorporated potentially
changing daily thrombotic and bleeding risks over the
ICU stay relevant to a broad case-mix of medical–surgical
patients.
We included a large number of centers in North America
enrolling a wide range of patients. By examining the lar-
gest and most heterogeneous group of medical–surgical
ICU patients to date, we enhanced the generalizability of
our findings. We conducted a pilot reliability study dem-
onstrating perfect agreement on 98% of collected variables
between two data abstractors, suggesting reliable data
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baseline premorbid conditions, and daily events and expo-
sures over the ICU stay that influence thromboprophy-
laxis prescribing. We calculated concordance, which takes
into account those who should and should not receive
prophylaxis. We used ICU patient-days as the unit of ana-
lysis for guideline concordance because this acknowledges
daily changes in a patient’s condition and drug prescribing,
rather than treating each patient as concordant or not
based on a threshold of concordance days [45]. We used
multilevel modeling, which allows concurrent analysis of
center and patient factors (fixed baseline characteristics
and variable patient-days) as determinants of administra-
tion, and avoided overfitting [46].Conclusions
In summary, in this 1-month multicenter audit of throm-
boprophylaxis administration in a large cohort of medical–
surgical critically ill patients, we documented widespread
use of anticoagulation in prophylactic or therapeutic doses,
greater use of UFH than LMWH, and mechanical prophy-
laxis primarily in patients who are bleeding or at risk of
bleeding. Guideline concordance with any type of anti-
coagulant was high (95.5% per ICU patient-day) and rea-
sons for noncompliance were poorly documented. Patients
who were sicker, heavier, have cancer, or have prior VTE
were more likely to receive pharmacological thrombopro-
phylaxis. Patients who were sicker, who had surgery, or
who received inotropes, vasopressors or renal replacement
therapy were less likely to receive LMWH than UFH,
representing a potential quality improvement target.Key messages
 UFH is more commonly used than LMWH for
thromboprophylaxis in medical–surgical critically ill
patients.
 Guideline concordance for pharmacological
thromboprophylaxis of any type is 95.5% per ICU
patient-day.
 Patients who were sicker, patients who were heavier,
and patients with cancer or prior thrombotic events
were more likely to receive pharmacological
thromboprophylaxis.
 Patients who were sicker, who had surgery, or who
received inotropes, vasopressors or renal
replacement therapy were less likely to receive
LMWH for thromboprophylaxis.Abbreviations
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